MOLECULAR RESPONSE
Molecular Response is an oncology research platform that comprises the largest collection of viable tumor specimens.
MOLECULAR RESPONSE
Industry:
Health Care Medical
Address:
San Diego, California, United States
Country:
United States
Status:
Active
Similar Organizations
Brevard Eye Center
Brevard Eye Center is an eye care healthcare centre that deals with the protection and care of eyes.
iCoreConnect
iCoreConnect is an online platform that provides secure communications solutions for the healthcare community.
NEXT Molecular Analytics
NEXT Molecular is a contract research organization that provides integrated research and development sciences and clinical testing services.
More informations about "Molecular Response"
Best Practices in Chronic Myeloid Leukemia Monitoring …
Assessment of molecular response (MR) by real-time quantitative polymerase chain reaction is the most sensitive way to monitor tyrosine kinase inhibitor (TKI) treatment efficacy.See details»
Molecular response in CML: where is the bar?
Jul 24, 2014 · For almost 10 years, the main goal of the treatment of CML with tyrosine kinase inhibitors (TKIs) has been the achievement of the so-called “major molecular response” (MMR; BCR-ABL1 ≤ 0.1% on the International Scale) 2 …See details»
Molecular response in newly diagnosed chronic-phase …
Tyrosine kinase inhibitor therapy revolutionized chronic myeloid leukemia treatment and showed how targeted therapy and molecular monitoring could be used to substantially improve survival outcomes.See details»
Molecular monitoring in CML: how deep? How often? How should …
Nov 30, 2018 · The duration and depth of molecular response have become synonymous with TFR eligibility. The term “complete molecular response,” implying undetectable BCR-ABL1 …See details»
Why is it critical to achieve a deep molecular response …
When patients successfully traverse the critical first 12 months of TKI therapy, most will head towards another milestone response, deep molecular response (DMR, BCR-ABL1 ≤0.01%). DMR is essential for patients aiming to achieve …See details»
New approaches to molecular monitoring in CML (and …
Nov 7, 2019 · CML is the “poster child” of genetically informed therapy because the unique chimeric BCR-ABL1 DNA, RNA, and protein is the target for tyrosine kinase inhibition and disease monitoring.See details»
Molecular monitoring in chronic myeloid leukemia—how low can …
Molecular monitoring of BCR-ABL1 transcripts for patients with chronic myeloid leukemia (CML) is now used to assess response to tyrosine kinase inhibitors (TKIs), including treatment failure …See details»
Patient-specific molecular response dynamics can predict the ...
Jul 22, 2022 · We develop a mathematical model to analyze and explain the outcomes of TFR 2. Our mathematical model framework can explain patient-specific molecular response …See details»
Successful maintenance of a sustained molecular response in CML ...
Jun 14, 2024 · Lowering the TKI dose can effectively preserve a deep molecular response over time while relieving adverse events caused by TKIs. Keywords: adverse events, chronic …See details»
European LeukemiaNet 2020 recommendations for treating …
Mar 3, 2020 · Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet …See details»
Deep Molecular Response Is Reached by the Majority of Patients …
Dec 2, 2013 · Deep molecular response (MR 4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after treatment …See details»
Major Molecular Response in Chronic Myeloid Leukemia (CML)
Mar 8, 2023 · Molecular response is one of the ways that doctors monitor the effectiveness of your CML treatment. It’s a measure of how many cells in your blood and bone marrow carry …See details»
Current Strategies and Future Directions to Achieve Deep …
CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a substantial number of patients who have achieved a …See details»
Chronic Myeloid Leukemia (CML) | Treatment Response | LLS
4.5-log reduction is referred to as a “complete molecular response (CMR)” or a “deep molecular response (DMR).” Doctors may refer to this as “MR4.5.” A 4.5-log reduction indicates that …See details»
How Do You Know If Treatment for Chronic Myeloid Leukemia Is …
Molecular response. Molecular response is based on how much of the BCR-ABL gene (which is found in CML cells) can be detected by the PCR test. This test can be done on either your …See details»
The initial molecular response predicts the deep molecular …
Using a real-world cohort of 408 patients, we compared the performance of the EUTOS long-term survival (ELTS) score, BCR::ABL1 HT, and residual disease at month 3 and 6 to predict the …See details»
Improving outcomes in chronic myeloid leukemia through …
Apr 8, 2021 · Immunological characterization in CML may help to develop novel immunotherapies that specifically target residual leukemic cells upon TKI discontinuation to improve TFR rates. …See details»
Relevant factors for policy concerning comprehensive genomic …
6 days ago · Most respondents agreed that the other sub-factors of the wider implications of diagnostic results, namely the refinement of a diagnosis based on molecular profiles and …See details»
Impact of Molecular Response at Specific Timepoints in Patients …
Nov 5, 2020 · Tyrosine kinase inhibitors (TKI) improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP), who meet molecular milestones at specific timepoints.See details»
Imatinib dose reduction after major molecular …
Sep 21, 2024 · In people with chronic-phase chronic myeloid leukemia (CML) receiving imatinib and achieving major molecular response (MMR), dose reduction may decrease adverse events but may be associated with a loss of …See details»